These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 21462364)

  • 1. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer.
    Kranzfelder M; Schuster T; Geinitz H; Friess H; Büchler P
    Br J Surg; 2011 Jun; 98(6):768-83. PubMed ID: 21462364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis.
    Pasquali S; Yim G; Vohra RS; Mocellin S; Nyanhongo D; Marriott P; Geh JI; Griffiths EA
    Ann Surg; 2017 Mar; 265(3):481-491. PubMed ID: 27429017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma.
    Morgan MA; Lewis WG; Casbard A; Roberts SA; Adams R; Clark GW; Havard TJ; Crosby TD
    Br J Surg; 2009 Nov; 96(11):1300-7. PubMed ID: 19847875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
    Gebski V; Burmeister B; Smithers BM; Foo K; Zalcberg J; Simes J;
    Lancet Oncol; 2007 Mar; 8(3):226-34. PubMed ID: 17329193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy.
    Karran A; Blake P; Chan D; Reid TD; Davies IL; Kelly M; Roberts SA; Crosby T; Lewis WG
    Br J Surg; 2014 Apr; 101(5):502-10. PubMed ID: 24615406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
    Sjoquist KM; Burmeister BH; Smithers BM; Zalcberg JR; Simes RJ; Barbour A; Gebski V;
    Lancet Oncol; 2011 Jul; 12(7):681-92. PubMed ID: 21684205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
    Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
    Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers.
    Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Klevebro F; Lindblad M; Ye W; Lundell L; Nilsson M
    Br J Surg; 2014 Mar; 101(4):321-38. PubMed ID: 24493117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer.
    Deng HY; Wang WP; Wang YC; Hu WP; Ni PZ; Lin YD; Chen LQ
    Eur J Cardiothorac Surg; 2017 Mar; 51(3):421-431. PubMed ID: 27694253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study.
    van der Woude SO; Hulshof MC; van Laarhoven HW
    Chin Clin Oncol; 2016 Feb; 5(1):13. PubMed ID: 26932437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma.
    Reid TD; Davies IL; Mason J; Roberts SA; Crosby TD; Lewis WG
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):617-24. PubMed ID: 22386923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer.
    Urschel JD; Vasan H; Blewett CJ
    Am J Surg; 2002 Mar; 183(3):274-9. PubMed ID: 11943125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes for Esophageal Squamous Cell Carcinoma Treated with Curative Intent in a Western Cohort: Should Multimodal Therapy Be the Gold Standard?
    Sheil F; Donohoe CL; King S; O'Toole D; Cunningham M; Cuffe S; Ravi N; Reynolds JV
    World J Surg; 2018 May; 42(5):1485-1495. PubMed ID: 29075858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy for resectable esophageal carcinoma: a meta-analysis of randomized clinical trials.
    Xu XH; Peng XH; Yu P; Xu XY; Cai EH; Guo P; Li K
    Asian Pac J Cancer Prev; 2012; 13(1):103-10. PubMed ID: 22502650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
    Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
    Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma.
    Wang BY; Wu SC; Chen HC; Hung WH; Lin CH; Huang CL; Chen HS
    Br J Surg; 2019 Feb; 106(3):255-262. PubMed ID: 30395362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis.
    Montagnani F; Fornaro L; Frumento P; Vivaldi C; Falcone A; Fioretto L
    Crit Rev Oncol Hematol; 2017 Jun; 114():24-32. PubMed ID: 28477744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.